Compare medmix AG with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a 6.93% CAGR growth in Operating Profits over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.37 times
- The company has been able to generate a Return on Equity (avg) of 3.30% signifying low profitability per unit of shareholders funds
2
Flat results in Jun 25
3
With ROE of 1.52%, it has a Very Expensive valuation with a 0.86 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
14.8%
0%
14.8%
6 Months
12.24%
0%
12.24%
1 Year
3.27%
0%
3.27%
2 Years
-27.34%
0%
-27.34%
3 Years
-21.45%
0%
-21.45%
4 Years
-26.75%
0%
-26.75%
5 Years
-28.02%
0%
-28.02%
medmix AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.98%
EBIT Growth (5y)
6.93%
EBIT to Interest (avg)
4.02
Debt to EBITDA (avg)
1.93
Net Debt to Equity (avg)
0.35
Sales to Capital Employed (avg)
0.63
Tax Ratio
0
Dividend Payout Ratio
63.69%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
5.43%
ROE (avg)
3.30%
Valuation key factors
Factor
Value
P/E Ratio
57
Industry P/E
Price to Book Value
0.86
EV to EBIT
19.08
EV to EBITDA
6.56
EV to Capital Employed
0.90
EV to Sales
1.17
PEG Ratio
1.67
Dividend Yield
NA
ROCE (Latest)
4.72%
ROE (Latest)
1.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
448.00
483.90
-7.42%
Operating Profit (PBDIT) excl Other Income
79.70
74.30
7.27%
Interest
9.00
11.80
-23.73%
Exceptional Items
-4.80
-11.90
59.66%
Consolidate Net Profit
7.00
-6.30
211.11%
Operating Profit Margin (Excl OI)
61.20%
37.00%
2.42%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -7.42% vs -0.55% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 211.11% vs -1,000.00% in Dec 2024
About medmix AG 
medmix AG
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






